Quick Answer
Monte Rosa Therapeutics, Inc. reported Total Assets of $448.66 million for the year ending 2025.
- Monte Rosa Therapeutics, Inc. showed an increase of +2.3% in Total Assets from 2024 to 2025.
- This data is from Monte Rosa Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $368.94 million | Q3 2021: $384.05 million | Q1 2022: $346.01 million | Q2 2022: $365.06 million | Q3 2022: $357.60 million | Q1 2023: $309.03 million | Q2 2023: $278.62 million | Q3 2023: $252.10 million | Q1 2024: $266.75 million | Q2 2024: $344.11 million | Q3 2024: $315.08 million | Q1 2025: $393.20 million | Q2 2025: $359.59 million | Q3 2025: $459.84 million.
- Over the full 6 years of available data (2020 to 2025), Monte Rosa Therapeutics, Inc.'s Total Assets has grown by 808.6%.
- Historical annual values: Fiscal year 2025: $448.66 million | Fiscal year 2024: $438.73 million | Fiscal year 2023: $303.76 million | Fiscal year 2022: $342.39 million | Fiscal year 2021: $366.33 million | Fiscal year 2020: $49.38 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: